
Ursodeoxycholic Acid Regulates Hepatic Energy Homeostasis …
Ursodeoxycholic acid (UDCA) is a hydrophilic bile acid (BA) and has been administered occasionally as a hepatoprotective drug for cholestasis and chronic hepatitis; it is also the drug approved by the United States Food and Drug Administration for the treatment of primary biliary cholangitis (PBC) [10, 11].
Different effects of ursodeoxycholic acid on intrahepatic cholestasis ...
2018年3月1日 · We found that UDCA (140 mg/kg) significantly aggravated liver injury from ANIT (100 mg/kg)-induced acute cholestasis study (data not shown). Thus, in the present study, we used 50 mg/kg ANIT for a moderate cholestasis model, and the dose of UDCA administered was selected from 25 mg/kg to 100 mg/kg.
Benefits of Ursodeoxycholic Acid: Uses, Dosage, & Side Effects
2024年8月12日 · Ursodeoxycholic acid tablet, also known as UDCA, is a secondary bile acid derived from cholesterol. It is primarily used to treat gallstones and certain liver diseases. Available in various forms, including tablets and syrups, UDCA is known for its ability to improve bile flow and reduce cholesterol saturation in bile.
【综述与讲座】熊脱氧胆酸在慢性肝病中应用及机制的再认识
2017年7月8日 · udca能显著降低被佛波酯或霍乱毒素上调的肝细胞生长因子mrna水平,部分抑制了肝细胞生长因子基因表达的上调(40%~50%),并在24 h和48 h范围内抑制超过80%霍乱毒素诱导的肝细胞生长因子产生 [67] 。在高浓度下,udca能显著抑制细胞增殖和更多的抗凋亡作用,而 …
Ursodeoxycholic Acid in Treatment of Non-cholestatic Liver …
Ursodeoxycholic acid (UDCA) is a non-toxic, hydrophilic bile acid indicated for treatment of gallstones and primary biliary cirrhosis (PBC). 1 Endogenous bile acids are hepatically synthesized and regulate cholesterol homeostasis and solubilization of dietary lipids.
生物法合成熊去氧胆酸研究进展_参考网 - fx361.cc
2024年4月10日 · 熊去氧胆酸 (UDCA)是一种内源性胆汁酸,具有溶解胆结石,治疗胆汁淤积、胆源性胰腺炎、原发性胆管炎、结肠炎 (癌)、 (非)酒精性肝炎、原发性胆汁性肝硬化、药物性肝炎和改善肝移植效果的作用 [1]。 最新研究发现,UDCA还可介导并影响癌症基因组中致癌信号通路调控,用于癌症治疗 [2];可特异性调控细胞凋亡阈值,诱导细胞自噬和凋亡,抑制癌细胞生长 [3];在治疗进行性神经系统疾病时,UDCA还能够改善受损线粒体功能,发挥神经保护作用 [4]。 新冠期间,UDCA还被 …
Protective effects of ursodeoxycholic acid on chenodeoxycholic …
2007年10月7日 · UDCA (50 mg/kg and 150 mg/kg) improved liver histology, with a significant decrease (679.3 ± 77.5 U/L vs 333.6 ± 50.4 U/L and 254.3 ± 35.5 U/L, respectively, P < 0.01) in serum ALT level. UDCA decreased the concentrations of the hydrophobic bile acids, and as a result, a decrease in the total bile acid level in the liver was achieved.
熊脱氧胆酸 - 百度百科
熊脱氧 胆酸 (ursodeoxycholic acid, UDCA):它是双羟基 胆汁酸 , 亲水性 ,在急性和 慢性肝炎 的应用正在扩大。 胆盐 促使水份、 卵磷脂 、 胆固醇 和 结合胆红素 从胆道排泄,熊脱氧胆酸盐比其它胆酸盐有大得多的利胆作用。
熊去氧胆酸 - 维基百科,自由的百科全书
熊去氧胆酸 (英語: Ursodeoxycholic acid,也被称为 3α,7β-二羟基-5β-胆烷-24-羧酸,3α,7β-dihydroxy-5β-cholan-24-oic acid, 缩写 UDCA),是一种来自 熊膽 的 胆汁酸 [1],为次级胆汁酸,在大部分动物体内由初级胆汁酸经由 细菌 代谢生成。 熊科 动物可以直接合成这种胆汁酸。 [2] 提纯的熊去氧胆酸在医学上用来溶解 胆结石 、 胆泥 (英语:biliary sludge),作用机理是增加胆汁内 胆固醇 的溶解度。 [3][4] 对于 原发性胆汁性胆管炎 、 [5] 原发性硬化性胆管炎 、 [6] 妊 …
The Effects of Intraperitoneal Administration of UDCA (25, 50, and …
Ursodeoxycholic acid (UDCA) is a hydrophilic bile acid that possesses many pharmacological effects, including increasing bile flow, changing the hydrophobicity of the bile acid...
- 某些结果已被删除